FDA clears Sequel's twiist for type 2 diabetes seven months after its type 1 launch
The Oct. 15 clearance, issued to DEKA Research and Development, extends the twiist Loop dosing algorithm to adults with insulin-treated type 2 diabetes. Sequel estimates the expansion adds about 5.5 million people in the U.S. who use insulin.

Seven months after launching its twiist automated insulin delivery system nationally for type 1 diabetes, Sequel Med Tech can offer it to a second group of patients. The Food and Drug Administration cleared twiist for adults with insulin-treated type 2 diabetes, Sequel disclosed Oct. 16, according to Healio and Drug Delivery Business.
FDA's database shows the 510(k) clearance, K262576, was issued Oct. 15 to DEKA Research and Development, which submitted the filing. It covers the twiist Loop algorithm, the dosing software that runs inside the pump.
Why it matters: The clearance takes twiist beyond type 1 diabetes for the first time. Sequel estimates it adds about 5.5 million people in the U.S. who manage the condition with insulin, Drug Delivery Business reported.
Under the new indications, the algorithm works with compatible integrated continuous glucose monitors and the twiist pump to automatically raise, lower and suspend basal insulin based on sensor readings and predicted glucose, and it can recommend correction doses that the user confirms. It remains indicated for type 1 diabetes in people 6 and older and now also covers type 2 diabetes in adults 18 and older.
The 510(k) summary says the algorithm itself was not changed from its predicate, DEKA's Loop algorithm cleared in March 2024 under K234055. FDA received the new submission July 27 and cleared it 80 days later, after review by the clinical chemistry panel. The device is classified as an interoperable automated glycemic controller under 21 CFR 862.1356, product code QJI.
DEKA supported the filing with a multicenter, single-arm trial of 307 adults with insulin-treated type 2 diabetes at 30 sites in 21 states, with the primary outcome measured at 13 weeks, according to the summary.
Sequel reported results in June: average HbA1c fell 0.7 percentage points from a baseline of 8.1%, time in the target glucose range rose to 73% from 57%, and no severe hypoglycemia events were reported. Those are the sponsor's figures. Drug Delivery Business reported that the results were published in Diabetes Care.
The twiist algorithm is based on Tidepool Loop, according to Sequel. FDA first cleared twiist in March 2024 for people 6 and older with type 1 diabetes, and Sequel brought it to market nationwide in March 2026, according to a company announcement.
Drug Delivery Business reported that twiist is compatible with Abbott's FreeStyle Libre 3 Plus and Senseonics' Eversense 365 continuous glucose monitors.
One open question for the type 2 rollout is how patients new to the technology take to it. At the start of the pivotal trial, only 19% of participants had used an automated insulin pump and 11% had experience counting carbohydrates, Sequel said, according to Drug Delivery Business.



